NCT05248646: An ongoing trial by Otsuka Pharmaceutical Development & Commercialization, Inc.
This trial is ongoing. It must report results 2 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05248646 |
|---|---|
| Title | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Sibeprenlimab Administered Subcutaneously in Subjects With Immunoglobulin A Nephropathy. |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 15, 2022 |
| Completion date | Dec. 30, 2026 |
| Required reporting date | Dec. 30, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |